Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AVAV +21.4%, ZX +21.2%, SCWX +14.5%, PLAY +7.3%, (also introduces new smaller store format of 15,000 to 20,000 square feet ), FNKO +4.3%, AEO +3.4%
M&A news:
- CLNT +110.9% (to acquire a 51% interest in the issued share capital of Brighten Holdings)
- DVA +8.8% (to sell its DaVita Medical Group unit to UnitedHealth's (UNH) Optum for approximately $4.9 bln in cash)
Other news:
- CLRB +25% (announces that the company will increase the targeted patient enrollment in the relapsed/refractory (R/R) multiple myeloma (MM) cohort of its currently enrolling Phase 2 clinical trial of CLR 131)
- ARWR +10.5% (Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy)
- NXTD +10.2% (Nxt-ID's Fit Pay and Garmin announced that the Garmin Pay contactless payment feature is now available for eligible Visa (V) accounts)
- GLBL +4.8% (TerraForm Global exercised right to extend termination date under Brookfield Asset Management (BAM) agreement and plan of merger to March 6, 2018 from December 6, 2017 )
- MYOS +4.7% (enters research agreement with the University of California)
- CHRS +2.9% (Coherus BioSciences discloses entry into Stock Purchase Agreement with KBI Biopharma)
- DISCA +2.5% (Guy Adami appeared on CNBC Fast Money with another 'Fast Pitch' -- this time on DISCA)
- AYX +2.5% (CEO featured on Tuesday's Mad Money)
- CLVS +2.3% ( FDA has accepted its sNDA for rucaparib and granted priority review status to the application with a PDUFA date of April 6, 2018)
- TIVO +2.2% (CEO/Pres disclosed the purchase of nearly 56K shares worth approx $999.6K)
Analyst comments:
- NVO +2.9% (upgraded to Buy from Neutral at BofA/Merrill)
- PEGI +1.5% (upgraded to Buy from Neutral at Goldman)
- CCL +0.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley)